Voronoi, Inc. (KOSDAQ:310210)
South Korea · Delayed Price · Currency is KRW 147,300
+600 (0.41%)
Sep 23, 2026, 3:30 PM KST
Voronoi Revenue
Voronoi had revenue of 4.16B KRW in the twelve months ending June 30, 2026, up 24.23% year-over-year. In the year 2025, Voronoi had annual revenue of 7.51B.
Revenue (ttm)
4.16B
Revenue Growth
+24.23%
P/S Ratio
637.00
Revenue / Employee
29.73M
Employees
140
Market Cap
2.65T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.51B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.77B | -5.02B | -33.93% |
| Dec 31, 2021 | 14.78B | 8.60B | 139.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| HLB Co., Ltd. | 97.47B |
| ABL Bio | 34.28B |
| OliX Pharmaceuticals | 13.64B |